Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Issue 8 (September 2017)

• Record Type: Journal Article
• Authors: Matsui, Hiroto; Hazama, Shoichi; Sakamoto, Kazuhiko; Shindo, Yoshitaro; Kanekiyo, Shinsuke; Nakashima, Masao; Matsukuma, Satoshi; Tokuhisa, Yoshihiro; Iida, Michihisa; Suzuki, Nobuaki; Yoshimura, Kiyoshi; Takeda, Shigeru; Ueno, Tomio; Yoshino, Shigefumi; Oka, Masaaki; Nagano, Hiroaki
• Is Part Of: Pancreas. Volume 46:Issue 8(2017)
• Publication Date: 2017-09
• Subjects: adoptive immunotherapy -- pancreatic cancer -- MUC1; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000000880
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: We previously described adoptive immunotherapy (AIT) with cytotoxic T lymphocytes (CTLs) stimulated by the mucin 1 (MUC1)–expressing human pancreatic cancer cell line YPK-1 (MUC1-CTLs) and demonstrated that MUC1-CTLs might prevent liver metastasis. In the present study, we combined gemcitabine (GEM) and AIT for the treatment of pancreatic cancer. Methods: A total of 43 patients who underwent radical pancreatectomy received treatment with MUC1-CTLs and GEM. After surgery, MUC1-CTLs were induced and administered intravenously 3 times, and GEM administered according to the standard regimen for 6 months. The patients whose relative dose intensity of GEM was 50% or more and who received 2 or more MUC1-CTL treatments were used as the adequate treatment group (n = 21). Results: In the adequate treatment group, disease-free survival was 15.8 months, and overall survival was 24.7 months. Liver metastasis was found only in 7 patients (33%), and local recurrence occurred in 4 patients (19%). The independent prognostic factor of long-term disease-free survival on multivariate analysis was the average number of CTLs administered ( P = 0.0133). Conclusions: The combination therapy with AIT and GEM prevented liver metastasis and local recurrence. Moreover, the disease free-survival was improved in patients who received sufficient CTLs.